phrykt

Bambusa Therapeutics, Inc. (BBTX): who owns it and who trades it

As of Nov 6, 2026, BBTX insiders reported 5 purchases worth $52.6M in the last 12 months. The largest buyer was Ra Capital Management, L.P. (Director), with $46.6M.

Latest filing Nov 6, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, BBTX insiders reported $52.6M of open-market purchases and $0 of sales.

Purchases, 12 months
$52.6M
5 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 2, 2026
Filed Nov 3, 2026

Purchases and sales by month

$46M$46MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 2, 2026Ra Capital Management, L.P. +4DirectorPurchase2.34M$16.00$37.4MForm 4
Nov 2, 2026Ra Capital Management, L.P. +4DirectorPurchase164,891$16.00$2.6MForm 4
Nov 2, 2026Helmut Wolfgang JeggleDirectorPurchase375,000$16.00$6MForm 4
Oct 30, 2026Ra Capital Management, L.P. +4DirectorPurchase189,909$14.23$2.7MForm 4
Oct 30, 2026Ra Capital Management, L.P. +4DirectorPurchase263,911$14.92$3.9MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ra Capital Management, L.P.Director, 10% owner$46.6M–Nov 2, 2026
Helmut Wolfgang JeggleDirector, 10% owner$6M–Nov 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

Bambusa Therapeutics company events

Bambusa Therapeutics filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.

  1. Nov 3, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BBTX in the last 120 days.

FiledHolderFormStake
Nov 6, 2026RA Capital Management, L.P.13D14.6%
Nov 6, 2026RA Capital Management, L.P.13D14.6%
Nov 5, 2026ATHOS KG13G9.0%
Nov 5, 2026ATHOS KG13G9.0%

Questions about Bambusa Therapeutics, Inc. (BBTX) stock

Are BBTX insiders buying or selling?

In the last 12 months, BBTX insiders reported 5 open-market purchases worth $52.6M and no sales. The latest trade was on Nov 2, 2026. See every trade.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.